Új-Zéland - angol - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - cefuroxime sodium 1537mg equivalent to 1500 mg cefuroxime anhydrous;   - powder for injection - 1500 mg - active: cefuroxime sodium 1537mg equivalent to 1500 mg cefuroxime anhydrous  

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - chlorhexidine acetate 0.02%{relative} - irrigation - 0.02 % - active: chlorhexidine acetate 0.02%{relative} excipient: glacial acetic acid water - latest regulatory activity

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

astrazeneca limited - bicalutamide 150mg - film coated tablet - 150 mg - active: bicalutamide 150mg excipient: hypromellose lactose monohydrate macrogol 300 magnesium stearate povidone purified water   sodium starch glycolate titanium dioxide

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - medroxyprogesterone acetate 150 mg/ml - injection (depot) - 150 mg/ml - active: medroxyprogesterone acetate 150 mg/ml excipient: hydrochloric acid macrogol 3350 methyl hydroxybenzoate polysorbate 80 propyl hydroxybenzoate sodium chloride sodium hydroxide - adjunctive and/or palliative treatment of recurrent and/or metastatic endometrial or renal carcinoma

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - fluconazole 150mg;   - capsule - 150 mg - active: fluconazole 150mg   excipient: colloidal silicon dioxide gelatin lactose monohydrate magnesium stearate maize starch

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

jntl consumer health (new zealand) limited - fluconazole 150mg;   - capsule - 150 mg - active: fluconazole 150mg   excipient: colloidal silicon dioxide gelatin lactose monohydrate magnesium stearate maize starch patent blue v tekprint black sw-9008 titanium dioxide - vaginal candidiasis.

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

viatris limited - venlafaxine hydrochloride 169.7mg equivalent to 150 mg venlafaxine;   - modified release capsule - 150 mg - active: venlafaxine hydrochloride 169.7mg equivalent to 150 mg venlafaxine   excipient: ethylcellulose gelatin hypromellose iron oxide red iron oxide yellow microcrystalline cellulose purified water tekprint white sb-0007p titanium dioxide - · efexor-xr is indicated for the treatment of major depression. efexor-xr is also indicated for the prevention of relapse and recurrence of major depression where appropriate.

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - fluconazole 150mg - capsule - 150 mg - active: fluconazole 150mg excipient: colloidal silicon dioxide gelatin   lactose magnesium stearate maize starch methyl hydroxybenzoate   patent blue v   propyl hydroxybenzoate   purified water   sodium laurilsulfate     titanium dioxide   - flucasten one 150 mg, given orally, is indicated for vaginal candidiasis.

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

viatris limited - fluconazole 150mg; fluconazole 150mg - capsule - 150 mg - active: fluconazole 150mg excipient: gelatin hydrated silica lactose monohydrate magnesium stearate pregelatinised maize starch sodium laurilsulfate tekprint black sw-9008 titanium dioxide active: fluconazole 150mg excipient: gelatin hydrated silica lactose monohydrate magnesium stearate maize starch sodium laurilsulfate tekprint black sw-9008 titanium dioxide - 1. cryptococcosis, including cryptococcal meningitis and infections of other sites (e.g. pulmonary, cutaneous). normal hosts, and patients with aids, organ transplants or other causes of immunosuppression may be treated. fluconazole can be used as maintenance therapy to prevent relapse of cryptococcal disease in patients with aids. 2. systemic candidiasis including candidaemia, disseminated candidiasis and other forms of invasive candidal infection including infections of the peritoneum, endocardium and pulmonary and urinary tracts. patients with malignancy, in intensive care units, receiving cytotoxic or immunosuppressive therapy, or with other factors predisposing to candidal infection may be treated. 3. mucosal candidiasis. these include oropharyngeal, oesophageal, non-invasive bronchopulmonary infections, candiduria, mucocutaneous and chronic oral atrophic candidiasis (denture sore mouth). normal hosts and patients with compromised immune function may be treated. 4. vaginal candidiasis, acute or recurrent. 5. prevention of fungal infection in immunocompromised patients considered at risk as a consequence of hiv infections or neutropenia following cytotoxic chemotherapy, radiotherapy or bone marrow transplant 6. fluconazole 50 mg & 150 mg capsules are also indicated for the treatment of dermatomycoses including tinea pedis, tinea corporis, tinea cruris, pityriasis versicolor & candidiasis.

Új-Zéland - angol - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - fluconazole 150mg - capsule - 150 mg - active: fluconazole 150mg excipient: colloidal silicon dioxide gelatin   lactose magnesium stearate maize starch methyl hydroxybenzoate   patent blue v   propyl hydroxybenzoate   purified water   sodium laurilsulfate     titanium dioxide